In this article, we explain how life sciences companies can evaluate SAP S/4HANA migration partners, assess validation capabilities, and reduce compliance risks in FDA-regulated environments.
Finding an SAP implementation partner has never been difficult. Finding one that can support an SAP S/4HANA migration in an FDA-regulated environment requires a much narrower search.
Life sciences companies operate under a different set of expectations than most industries. Migration decisions affect validated systems, regulated data, quality processes, and inspection readiness. A project plan that looks complete from an IT perspective may leave significant gaps from a quality or regulatory perspective.
In this article, we will discuss how to evaluate SAP S/4HANA migration partners for pharmaceutical, biotechnology, and medical device organizations in the United States. We will also cover the capabilities, validation expertise, and compliance controls that deserve scrutiny before a migration begins.
SAP runs deep in life sciences organizations. Pharmaceutical manufacturers use it to manage batch records, materials procurement, and quality event workflows. Biotech firms run clinical supply chains and deviation tracking through it. Medical device companies depend on it for complaint handling, CAPA workflows, and traceability documentation under 21 CFR Part 820.
The platform underpins how regulated work gets done, which is precisely what makes migrating it a different category of project.
From a technical standpoint, moving to SAP S/4HANA means transitioning from SAP ECC or another legacy ERP to a modern architecture, often through RISE with SAP, SAP's managed cloud migration program. From a regulatory standpoint, that same migration reaches into processes and data the FDA considers part of a validated state. Those processes carry obligations that cannot be deferred or reconstructed after go-live.
Computer systems in GxP (Good Manufacturing Practice, Good Laboratory Practice, Good Clinical Practice) environments must comply with standards set by the FDA for data integrity, audit trail completeness, and process control. In 21 CFR Part 11 for electronic records and electronic signatures, this requirement is made official. The GAMP 5 framework, published by ISPE, provides the industry-standard methodology for structuring and documenting validation across automated systems.
When an ERP migrates, the systems of record for batch release decisions, laboratory results, supplier qualification data, and production deviation logs all change. Each carries validation obligations. A migration that alters how data is stored, accessed, or displayed, even when the change is unintentional, can break a validated state that took years to establish. Restoring it afterward requires retroactive documentation, data remediation, and re-qualification work that can run for months.
The FDA inspects manufacturing sites, laboratories, and clinical operations. When inspectors identify data integrity problems, they trace those problems to their source, and ERP systems appear regularly in that chain. FDA Form 483 observations and Warning Letters have cited issues directly connected to ERP environments, including:
An S/4HANA migration meets the threshold for a significant change under most validated change control frameworks. That classification triggers a formal validation effort, which runs parallel to, and is separate from, standard functional testing and user acceptance.
RISE with SAP consolidates S/4HANA licensing, infrastructure, and managed services under a single contract. For life sciences organizations, adopting this model raises compliance questions that go beyond standard cloud procurement decisions.
When GxP-critical systems move to a cloud or private cloud environment, the organization retains full responsibility for their validated state. SAP manages the underlying infrastructure.
The implementation partner and the customer remain jointly accountable for ensuring that the migrated system meets regulatory requirements and that GxP compliance controls remain operational throughout the transition. That division of responsibility must be explicitly defined, documented, and aligned with the organization's Quality Management System before migration begins.
Whether the implementation partner understands how to structure that accountability — and whether it has done so before under FDA scrutiny — is what separates a technically capable vendor from a genuinely qualified one.
Strong SAP credentials and life sciences validation experience are two separate things, although most vendor selection processes treat them as one. A partner can carry certified consultants across FI, MM, SD, PP, and QM, a long list of S/4HANA go-lives, and still have no structured approach to GxP change control or IQ/OQ/PQ execution.
That gap rarely surfaces during contract negotiations. It shows up months into delivery.
For most IT-focused SAP partners, validation enters the conversation late. Their project methodology prioritizes system build, data migration, integration testing, and user acceptance testing. Validation documentation — when it appears in the project plan at all — typically sits as a separate workstream, handed off to the client's internal quality team or a third-party consultant after the system has been built.
This creates a specific structural problem. GAMP 5 and the FDA's Computer Software Assurance (CSA) guidance, updated in 2022, frame validation as a series of decisions made during design, configuration, and development. Documenting those decisions after the system has been built produces records that are incomplete, because the decisions themselves are no longer fully traceable.
An FDA inspector reviewing audit trail configuration will ask when that configuration was defined, tested, and formally approved. If the answer points to a period after go-live, the documentation will not hold.
A life sciences SAP partner structures the project differently from the outset. Validation engineers work alongside functional consultants during the design phase. User Requirements Specifications and Functional Specifications are written with GxP traceability built in. Configuration decisions that affect regulated processes are documented under formal change control before transports reach production.
IQ/OQ/PQ protocols are drafted during the build phase and executed during system integration testing, not scheduled for a later date. Data migration for regulated records, including batch data, laboratory results, quality events, and supplier qualification records, follows a validated migration approach that includes migration qualification and data reconciliation against the source system.
The FDA's 2022 CSA guidance also shifted the industry's approach from documentation-heavy validation toward risk-based assurance, with testing effort calibrated to the criticality of each function. A life sciences specialist applies this by concentrating validation work on GxP-critical processes, while applying lighter-touch assurance to lower-risk areas, which reduces overall validation effort without reducing compliance coverage.
Change control represents the most consistent point of failure in ERP migrations run by non-specialist partners. In a GxP environment, any modification to a validated system, whether a configuration change, a code transport, or a system parameter adjustment, requires documented impact assessment and formal approval before it is applied to a validated environment.
General SAP integrators work within standard IT change management frameworks. These frameworks track what changed and when, but they do not capture GxP-required elements: the validation impact assessment, the risk classification, the approver chain that includes quality involvement, and the link back to the original validated baseline. The following areas reflect where this difference becomes consequential in an S/4HANA migration:
A partner without embedded GxP change control processes will deliver these changes efficiently from a project management perspective. From a regulatory perspective, each undocumented change becomes a gap that requires retroactive remediation or, if identified during inspection, a formal corrective and preventive action.
General Integrators vs. Life Sciences SAP Validation Experts
|
Capability |
General SAP integrator |
Life sciences validation specialist |
|
GAMP 5 Lifecycle Understanding |
Aware of the framework, but rarely applies it structurally to project delivery |
Integrates GAMP 5 phases into design, build, and testing sprints from day one |
|
21 CFR Part 11 Expertise |
Treats it as a configuration checklist; audit trail activation is a technical task |
Designs electronic records and signature workflows against Part 11 requirements during the blueprint phase |
|
Audit Trail Deployment Experience |
Configured post-build or delegated to the client's QA team |
Verified, tested, and documented as part of OQ protocols before go-live |
|
Post-Go-Live Change Control |
Follows standard IT change management; GxP impact assessments are absent |
Every transport and configuration change in a validated environment goes through documented GxP change control with quality approval |
Before you put out an RFP or begin vendor evaluation, it’s good to understand what capabilities really distinguish a life sciences SAP partner from a generalist. The five criteria listed below are not abstract preferences. Each targets a specific failure mode we have seen repeatedly in FDA-regulated S/4HANA migrations where the wrong partner is chosen.
GAMP 5 Second Edition, released by ISPE in 2022, shifted the validation framework further toward risk-based thinking and away from documentation volume as a proxy for compliance rigor. A qualified partner uses this to make deliberate decisions early: which systems and processes are GxP-critical, what level of testing those functions require, and where lighter-touch assurance is appropriate without reducing compliance coverage.
In practice, this means the partner produces a Validation Master Plan before configuration begins. System and process risk classifications are established during blueprinting. Testing protocols are written against those classifications, not generated generically after the system is built. A partner who cannot explain how they apply risk categorization to SAP module configuration has not embedded GAMP 5 into their delivery methodology.
21 CFR Part 11 compliance in a cloud ERP environment is a configuration exercise as much as it is a regulatory one. SAP S/4HANA provides native technical controls for electronic records and signatures, but those controls require deliberate setup, testing, and documentation to meet FDA requirements.
A qualified partner demonstrates specific experience configuring audit trail activation across GxP-relevant modules, including QM, PP, and MM. They implement role-based access control at a granularity that prevents unauthorized data modification and supports traceability to individual users. Where electronic signatures are required for batch release, deviation approval, or CAPA closure, the implementation must meet Part 11's requirements for signature meaning, identity verification, and record linkage. These are not default settings. They require consultants who have configured them before and documented them to a standard that holds up under inspection.
General S/4HANA delivery experience does not transfer automatically to life sciences-specific functionality. Three areas in particular require demonstrated expertise rather than general module familiarity.
SAP Advanced Track and Trace for Pharmaceuticals (ATTP) handles serialization and aggregation data for Drug Supply Chain Security Act (DSCSA) compliance. DSCSA's interoperability requirements became fully enforceable in 2024, and correct ATTP configuration requires an understanding of how serialization data flows between manufacturers, wholesalers, and dispensers. SAP QM configured for pharmaceutical or medical device environments must support CAPA workflows, deviation management, and stability study tracking in a way that aligns with 21 CFR Part 211 or Part 820.
Electronic Batch Records, whether managed natively in SAP or integrated with a dedicated EBR system, require data integrity controls and audit trail coverage that extend across the full batch lifecycle.
A partner who has delivered these capabilities in validated environments will provide references and documentation examples. One who has not will describe them in general terms.
RISE with SAP includes regular system updates managed by SAP. In a standard IT environment, this is straightforward. In a validated environment, each update that touches a GxP-critical function requires impact assessment, change control documentation, and potentially re-testing before it can be accepted into the production system.
A partner with a clean core strategy addresses this by keeping custom development off the S/4HANA core and building extensions through SAP Business Technology Platform (BTP) instead. When the core remains standard, SAP-delivered updates carry lower validation risk because they do not interact with custom code. The partner should be able to explain their approach to:
This clean core approach is also what makes long-term compliance sustainable, because it prevents the accumulation of custom code that makes every future upgrade a renegotiation with the validation team.
The FDA's 2022 CSA draft guidance moved away from the earlier expectation that the validation effort should be measured by the volume of scripted test cases. CSA replaces that model with a risk-based testing approach that concentrates formal scripted testing on critical functions and relies on unscripted exploratory testing for lower-risk areas.
A partner who has absorbed this shift designs their test strategy differently. Scripted IQ, OQ, and PQ protocols cover functions where data integrity, electronic records, or patient safety are directly at stake. Automated testing tools, such as SAP's own Solution Manager testing capabilities or third-party tools like Tricentis Tosca, handle regression testing across large functional areas at speed.
This reduces the overall validation documentation burden while maintaining defensible coverage where it matters. A partner still running hundred-page scripted test scripts uniformly across all system functions is applying a methodology the FDA explicitly avoids.
Selecting the right partner reduces risk, but it does not eliminate it. SAP S/4HANA programs remain complex initiatives that involve large volumes of regulated data, interconnected systems, and multiple stakeholder groups.
Many problems in SAP implementation projects within life sciences do not originate from system configuration. They emerge when organizations underestimate the effort required to preserve traceability, validate integrations, and maintain project continuity throughout the migration lifecycle.
Data migration often receives attention from a technical perspective. Validation teams face a different challenge.
Historical batch records, material genealogy data, laboratory results, supplier qualification records, and quality event histories frequently support regulatory decisions long after their original creation. During migration, organizations must demonstrate that this information remains complete, accurate, and traceable within the new environment.
A successful migration strategy should include:
These controls help preserve data integrity within the ERP environment and support inspection readiness after go-live.
SAP S/4HANA rarely operates in isolation. Most life sciences organizations maintain connections with laboratory information management systems (LIMS), manufacturing execution systems (MES), warehouse platforms, serialization repositories, and external quality systems.
Each interface introduces potential validation concerns. Data exchanged between systems must remain complete, accurate, and synchronized. Error-handling procedures require a clear definition. User actions and automated transactions should remain traceable across system boundaries.
For this reason, integration validation deserves the same level of planning as core ERP validation. Waiting until end-to-end testing to evaluate interfaces often exposes issues that are expensive to correct late in the project.
Large SAP programs can span multiple years. During that period, project teams often change as consultants rotate to new engagements or specialized resources leave the project.
This creates a challenge for regulated implementations. Validation decisions, risk assessments, design rationales, and testing strategies depend heavily on institutional knowledge accumulated throughout the program.
Organizations can reduce this risk by defining key project roles during contract negotiations and establishing expectations for continuity among senior architects, validation leads, and quality-focused delivery personnel. Documentation remains essential, but documentation alone cannot replace the experience of team members who participated in critical design and validation decisions.
These three areas deserve particular attention because they affect the evidence organizations rely on during audits, inspections, and internal quality reviews. Strong governance, disciplined validation practices, and experienced project leadership help prevent issues that become difficult and costly to address after deployment.
Every SAP S/4HANA migration partner will present certifications, methodologies, and project references. The more useful question is whether the team can support both implementation and validation activities in a regulated environment.
Use the decision tree below to evaluate the capabilities that matter most for life sciences organizations.
LeverX helps pharmaceutical, biotech, and medical device companies with SAP S/4HANA migration projects. Our teams combine SAP implementation expertise with knowledge of validation, regulated processes, data migration, and system integration.
For organizations preparing for a migration, an early assessment can help identify validation requirements, project risks, and planning priorities before implementation begins.
Speak with our experts to discuss your SAP S/4HANA roadmap.